- Record: found
- Abstract: found
- Article: not found
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
M K B Parmar ,
J A Ledermann ,
N Colombo ,
A du Bois ,
J-F Delaloye ,
G B Kristensen ,
S Wheeler ,
A M Swart ,
W Qian ,
V Torri ,
I Floriani ,
G Jayson ,
A Lamont ,
C Tropé
Jun 21 2003
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment.